Savara Inc (SVRA)

$5.23 -0.02 (-0.38%)
Market Cap 1.07B
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,319,200
Avg Vol 1,492,962
Day's Range N/A - N/A
Shares Out 203.47M
Stochastic %K 18%
Beta 0.31
Analysts Strong Sell
Price Target $10.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
Richterscale
Richterscale Mar. 16 at 6:56 PM
$SVRA IMO it gets a merger or buyout.
0 · Reply
StreetwiseReports
StreetwiseReports Mar. 16 at 6:43 PM
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch https://ow.ly/PFml50YuXaM H.C. Wainwright reiterated its rating and price target on Savara Inc. ($SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.
0 · Reply
ckruel
ckruel Mar. 16 at 4:22 PM
$SVRA https://tipranks.onelink.me/WJho/0wis4ym9 Another analyst target
0 · Reply
ckruel
ckruel Mar. 16 at 1:24 PM
$SVRA He also underscores the parallel progress ex-U.S., with marketing applications now submitted to both the EMA and the U.K. regulator, positioning the drug for broader international uptake and reinforcing its commercial potential. Coupled with Savara’s solid balance sheet, current cash of roughly $236 million, and access to substantial non-dilutive capital upon approval, he views the company as well funded for launch execution and maintains an Outperform rating with meaningful upside to his $11 price target.
0 · Reply
ckruel
ckruel Mar. 16 at 1:24 PM
$SVRA Francois Brisebois has given his Buy rating due to a combination of factors tied to Savara’s lead asset, MOLBREEVI, and its regulatory momentum. He highlights the recent FDA Day 74 letter confirming no advisory committee and ongoing priority review of the BLA, alongside strong Phase 3 data showing statistically significant and durable efficacy in aPAP, which together underpin his high confidence in U.S. approval by the August 22, 2026 PDUFA date.
0 · Reply
ckruel
ckruel Mar. 16 at 1:22 PM
$SVRA Savara, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on the stock and has a $11.00 price target.
0 · Reply
BioGem
BioGem Mar. 14 at 11:46 PM
$SVRA Shortable above $5, many critical negatives. Accounting for the additional 48.6M vested pre-funded warrants the outstanding shares are near 254M and a mkt cap at 1.35B. Extremely expensive: -Bottom line and operating losses are accelerating already. -Costs will skyrocket in H2 26 when they build a marketing and sales team. -Expect to run out of cash and raise funds through expensive debt with covenants. -Adoption will be slow for several quarters into late 2027, including insurance coverage dragging on. -Stock options and RSU are all deep in the money and will dilute hugely the shares o/s. -No prestigious biotech fund is invested. -Short ratio is huge = consensus of poor performance.
4 · Reply
art62
art62 Mar. 13 at 3:34 PM
$SVRA so he sees a double from here
0 · Reply
art62
art62 Mar. 13 at 3:32 PM
$SVRA ATsai Jefferiies "We remain 90%+ confident in the US approval of Molbreevi (inhaled GM-CSF) in aPAP rare lung disease by Aug 22, 2026 PDUFA ($500M+ oppty). With mgmt's patient-finding efforts providing line of sight to 1000+ patients, we foresee an initial bolus shortly after a pot'l Sep 2026 launch. Notably, mgmt sounds comfortable with the first twelve-month cons of $70-80M. Net-net, $500M sales x 4-5x multiple (biosimilars are unlikely) = $2.0-2.5B valuation (vs $1.2B cap)."
0 · Reply
StockNews_Live
StockNews_Live Mar. 13 at 12:05 PM
$SVRA 🎯 STOCK NEWS ALERT 💵 Price: $5.33 (-3.80%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Savara Inc. reported financial results for the fourth quarter and full year ending December 31, 2025, and provided a business update. The company achieved regulatory milestones for the MOLBREEVI… 📎 https://stocknews.live/news/SVRA/savara-reports-fourth-quarter-94437.html
0 · Reply
Latest News on SVRA
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 13, 2026, 8:05 AM EDT - 3 days ago

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 6, 2026, 4:05 PM EST - 10 days ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Mar 4, 2026, 4:05 PM EST - 12 days ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 20, 2026, 4:15 PM EST - 24 days ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces New Employment Inducement Grant

Feb 13, 2026, 4:05 PM EST - 4 weeks ago

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Feb 4, 2026, 4:05 PM EST - 5 weeks ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 6 weeks ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 5:16 AM EST - 2 months ago

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 2 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 3 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 3 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 3 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 3 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara: A High-Risk Opportunity

Nov 16, 2025, 6:35 AM EST - 4 months ago

Savara: A High-Risk Opportunity

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 4 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 4 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 4 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 4 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 4 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 5 months ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 5 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 5 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 9, 2025, 7:42 AM EDT - 5 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 6 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 6 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 7 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 7 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:05 AM EDT - 7 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Richterscale
Richterscale Mar. 16 at 6:56 PM
$SVRA IMO it gets a merger or buyout.
0 · Reply
StreetwiseReports
StreetwiseReports Mar. 16 at 6:43 PM
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch https://ow.ly/PFml50YuXaM H.C. Wainwright reiterated its rating and price target on Savara Inc. ($SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.
0 · Reply
ckruel
ckruel Mar. 16 at 4:22 PM
$SVRA https://tipranks.onelink.me/WJho/0wis4ym9 Another analyst target
0 · Reply
ckruel
ckruel Mar. 16 at 1:24 PM
$SVRA He also underscores the parallel progress ex-U.S., with marketing applications now submitted to both the EMA and the U.K. regulator, positioning the drug for broader international uptake and reinforcing its commercial potential. Coupled with Savara’s solid balance sheet, current cash of roughly $236 million, and access to substantial non-dilutive capital upon approval, he views the company as well funded for launch execution and maintains an Outperform rating with meaningful upside to his $11 price target.
0 · Reply
ckruel
ckruel Mar. 16 at 1:24 PM
$SVRA Francois Brisebois has given his Buy rating due to a combination of factors tied to Savara’s lead asset, MOLBREEVI, and its regulatory momentum. He highlights the recent FDA Day 74 letter confirming no advisory committee and ongoing priority review of the BLA, alongside strong Phase 3 data showing statistically significant and durable efficacy in aPAP, which together underpin his high confidence in U.S. approval by the August 22, 2026 PDUFA date.
0 · Reply
ckruel
ckruel Mar. 16 at 1:22 PM
$SVRA Savara, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on the stock and has a $11.00 price target.
0 · Reply
BioGem
BioGem Mar. 14 at 11:46 PM
$SVRA Shortable above $5, many critical negatives. Accounting for the additional 48.6M vested pre-funded warrants the outstanding shares are near 254M and a mkt cap at 1.35B. Extremely expensive: -Bottom line and operating losses are accelerating already. -Costs will skyrocket in H2 26 when they build a marketing and sales team. -Expect to run out of cash and raise funds through expensive debt with covenants. -Adoption will be slow for several quarters into late 2027, including insurance coverage dragging on. -Stock options and RSU are all deep in the money and will dilute hugely the shares o/s. -No prestigious biotech fund is invested. -Short ratio is huge = consensus of poor performance.
4 · Reply
art62
art62 Mar. 13 at 3:34 PM
$SVRA so he sees a double from here
0 · Reply
art62
art62 Mar. 13 at 3:32 PM
$SVRA ATsai Jefferiies "We remain 90%+ confident in the US approval of Molbreevi (inhaled GM-CSF) in aPAP rare lung disease by Aug 22, 2026 PDUFA ($500M+ oppty). With mgmt's patient-finding efforts providing line of sight to 1000+ patients, we foresee an initial bolus shortly after a pot'l Sep 2026 launch. Notably, mgmt sounds comfortable with the first twelve-month cons of $70-80M. Net-net, $500M sales x 4-5x multiple (biosimilars are unlikely) = $2.0-2.5B valuation (vs $1.2B cap)."
0 · Reply
StockNews_Live
StockNews_Live Mar. 13 at 12:05 PM
$SVRA 🎯 STOCK NEWS ALERT 💵 Price: $5.33 (-3.80%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Savara Inc. reported financial results for the fourth quarter and full year ending December 31, 2025, and provided a business update. The company achieved regulatory milestones for the MOLBREEVI… 📎 https://stocknews.live/news/SVRA/savara-reports-fourth-quarter-94437.html
0 · Reply
Flydown
Flydown Mar. 13 at 7:29 AM
$SVRA a lot patience!
0 · Reply
Richterscale
Richterscale Mar. 10 at 6:59 PM
$SVRA Bots now trolls. Some actual activity! Lol
0 · Reply
Richterscale
Richterscale Mar. 10 at 4:40 PM
$SVRA News?
0 · Reply
ghostdemon
ghostdemon Mar. 10 at 12:42 PM
$SVRA scam
0 · Reply
Richterscale
Richterscale Mar. 7 at 9:56 PM
$SVRA when are we getting back to $7?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 7 at 7:36 AM
$SVRA trading at $5.27, with average volume of 1.7M. Recent volume around 763.1k - 1.3M range.
0 · Reply
art62
art62 Mar. 7 at 2:47 AM
$SVRA now I see ckruel already posted- oops
0 · Reply
art62
art62 Mar. 7 at 2:44 AM
$SVRA oh sorry and- A “Day 74 Letter” is a standard milestone in the review process for a Biologics License Application (BLA) submitted to the U.S. Food and Drug Administration under the Prescription Drug User Fee Act (PDUFA) framework.
0 · Reply
art62
art62 Mar. 7 at 2:42 AM
$SVRA external advisory panel - i deem unlikely but maybe formality..dot i cross t's
0 · Reply
art62
art62 Mar. 7 at 2:39 AM
$SVRA Translation basically means: The FDA accepted the MOLBREEVI BLA for full review. The agency does not currently plan an external advisory panel. The decision deadline is August 22, 2026. It is neutral-to-positive regulatory news
0 · Reply
art62
art62 Mar. 7 at 2:38 AM
$SVRA Day 74 Letter from the FDA which indicated that an Advisory Committee meeting is not planned for the MOLBREEVI Biologics License Application (BLA) and the review is ongoing with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026.
0 · Reply
ckruel
ckruel Mar. 6 at 10:37 PM
$SVRA https://finance.yahoo.com/news/savara-provides-regulatory-molbreevi-development-210500711.html
1 · Reply